Bailard’s Organogenesis Holdings ORGO Stock Holding History

Bailard’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-36,812	Closed	-$87.2K	–	830
2026 Q1	$87.2K	Hold	36,812	–	–	﹤0.01%	729
2025 Q4	$191K	Sell	36,812 -6,101	-14%	-$29.6K	﹤0.01%	722
2025 Q3	$181K	Hold	42,913	–	–	﹤0.01%	740
2025 Q2	$157K	Hold	42,913	–	–	﹤0.01%	728
2025 Q1	$185K	Hold	42,913	–	–	﹤0.01%	701
2024 Q4	$137K	Hold	42,913	–	–	﹤0.01%	708
2024 Q3	$123K	Buy	+42,913	New	+$120K	﹤0.01%	723
2024 Q2	–	Sell	-40,400	Closed	-$115K	–	792
2024 Q1	$115K	Buy	40,400 +4,500	+13%	+$15.3K	﹤0.01%	720
2023 Q4	$147K	Buy	+35,900	New	+$101K	﹤0.01%	674
2022 Q3	–	Sell	-27,900	Closed	-$136K	–	733
2022 Q2	$136K	Buy	+27,900	New	+$172K	0.01%	641

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bailard's ORGO Position: Q2 2026 in Review

Bailard sold out of Organogenesis Holdings (ORGO) in Q2 2026, closing a stake of 36,812 shares — an estimated $87.2K sold.

Bailard first reported a position in ORGO in Q2 2022 and held it in 10 quarters. The position peaked at $191K in Q4 2025. 134 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

Bailard reported no remaining Organogenesis Holdings position as of Q2 2026 after selling out during the quarter.
Bailard sold 36,812 Organogenesis Holdings shares in Q2 2026, an estimated $87.2K.
Bailard first reported a position in Organogenesis Holdings in Q2 2022 and held it in 10 quarters.
Bailard's Organogenesis Holdings position peaked at $191K in Q4 2025.
134 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.